Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

A 26-year-old male shared results after using Minoxidil twice daily and dermarolling weekly for two months, seeking advice on additional treatments for better hair growth. Another user discussed their experience with finasteride and considered trying dutasteride due to concerns about hair shedding and lack of regrowth.

The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.

The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.

The user is considering getting blood work to investigate the cause of ongoing hair loss despite using finasteride and dutasteride. Others suggest that while blood tests can provide useful health information, they may not change the hair treatment outcome.

A 47-year-old man has been using a topical spray containing minoxidil, finasteride, biotin, and ketoconazole for hair loss but has not seen any regrowth and is experiencing more hair loss. He is considering switching to a pill form due to frustration with the lack of results.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.

Zeuss sublingual products for hair loss, including finasteride and a finasteride-free option, are discussed for their potential to reduce side effects through sublingual delivery. The inclusion of copper peptides is noted, but the high price is a concern without more user feedback.

A 33-year-old is considering switching from topical finasteride to oral finasteride due to application difficulties with long hair. They are concerned about potential shedding with oral finasteride and are seeking advice on dosage and whether their crown shows signs of thinning.

The user experienced significant hair thickening and temple hair growth after one year of using finasteride, minoxidil, and weekly dermarolling. They are considering asking their dermatologist about dutasteride.

Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.

The user has been using topical finasteride for seven months and minoxidil for three years, with added tretinoin gel for ten months, and is experiencing continuous shedding without signs of regrowth. They are questioning if the amount of shedding is normal at this stage of treatment and if there's a correlation between finasteride response and the rate of hair loss.

Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.

A 20-year-old has been using oral dutasteride for 6 months, topical minoxidil for a year, ketoconazole shampoo for a year, and dermarolling every 2 weeks for a year to treat hair loss. They are questioning the effectiveness and value of these treatments and seeking advice on whether to continue.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The conversation is about purchasing Cb-03-01 for research purposes. The user seeks advice on where and how to buy it outside the U.S.

Dutasteride and oral minoxidil are commonly used in Spain for hair loss, with a typical dose of 0.5 mg dutasteride and 2.5-5 mg oral minoxidil. Some users report side effects like erectile dysfunction when using finasteride and minoxidil.

The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.

The conversation discusses the effectiveness of dermastamps versus dermarollers for hair loss treatment, with some users preferring dermastamps for precision and less hair damage. One user reports using a dermastamp with minoxidil, while others mention the convenience of dermapens and the cost-effectiveness of dermarollers.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

A user reported increased shedding and some side effects like ball ache and potential watery semen after taking 0.25mg of finasteride daily for two months, but noted a high sex drive and considered the shedding a possible sign of new hair growth. Other users discussed dosage differences, with some suggesting starting with a smaller dose and monitoring effects, while others shared their experiences with no shedding or hair growth yet.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

The user has tried various hair loss treatments including oral finasteride, oral dutasteride, topical and oral minoxidil, pyrilutamide, and RU58841, and is inquiring about other popular treatments. Another user responded humorously, questioning the original poster's age and the pattern of their hair loss.

The post discusses an 11-month hair loss treatment journey using dutasteride, minoxidil, nizoral, and 1.5mm derma rolling. The responses inquire about the frequency of derma rolling and express optimism for further progress.

The user is documenting their hair loss progress using 0.5mg oral dutasteride daily. They shared pictures and received encouragement.

A user's plan to use Zix and topical finasteride (5AR inhibitors) for hair loss, followed by blood testing before/after. The user has suggested creating a fund to cover part of the cost of their blood tests. Replies to their post discuss the effectiveness of the treatments.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The conversation is about hair regrowth results after two months using oral finasteride, oral and topical minoxidil, and weekly dermarolling. The user shared before and after photos to show progress.